Cargando…

What is the added value of FeNO as T2 biomarker?

There is increasing evidence about the role of nitric oxide in type 2 (T2) immune response. Fraction of exhaled nitric oxide (FeNO) is a product of airways inflammation and it is increased in patients with asthma. Since Gustaffson published the first article about this biomarker in the 1990s, intere...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcos, María Celeste, Cisneros Serrano, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403133/
https://www.ncbi.nlm.nih.gov/pubmed/36032508
http://dx.doi.org/10.3389/falgy.2022.957106
_version_ 1784773304174772224
author Marcos, María Celeste
Cisneros Serrano, Carolina
author_facet Marcos, María Celeste
Cisneros Serrano, Carolina
author_sort Marcos, María Celeste
collection PubMed
description There is increasing evidence about the role of nitric oxide in type 2 (T2) immune response. Fraction of exhaled nitric oxide (FeNO) is a product of airways inflammation and it is increased in patients with asthma. Since Gustaffson published the first article about this biomarker in the 1990s, interest has continued to grow. Compared with other T2 biomarkers such as blood eosinophil count, induced sputum, or serum periostin, FeNO has some remarkable advantages, including its not invasive nature, easy repeatability, and possibility to be performed even in patients with severe airway obstruction. It is considered as an indicator of T2 inflammation and, by the same token, a useful predictor for inhaled steroid response. It is difficult to determine the utility of nitric oxide (NO) for initial asthma diagnosis. In such a heterogenous disease, a single parameter would probably not be enough to provide a complete picture. There is also an important variability among authors concerning FeNO cutoff values and the percentage of sensibility and specificity for diagnosis. Its high specificity indicates a potential role to “rule in” asthma; however, its lower sensibility could suggest a lower capacity to “rule out” this pathology. For this reason, if a diagnosis of asthma is being considered, FeNO should be considered along with other tests. FeNO has also shown its utility to detect response to steroids, adherence to treatment, and risk of exacerbation. Even though there is not enough quality of evidence to establish overall conclusions, FeNO could be an alternative procedure to diagnose or exclude asthma and also a predictive tool in asthma treated with corticosteroids.
format Online
Article
Text
id pubmed-9403133
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94031332022-08-26 What is the added value of FeNO as T2 biomarker? Marcos, María Celeste Cisneros Serrano, Carolina Front Allergy Allergy There is increasing evidence about the role of nitric oxide in type 2 (T2) immune response. Fraction of exhaled nitric oxide (FeNO) is a product of airways inflammation and it is increased in patients with asthma. Since Gustaffson published the first article about this biomarker in the 1990s, interest has continued to grow. Compared with other T2 biomarkers such as blood eosinophil count, induced sputum, or serum periostin, FeNO has some remarkable advantages, including its not invasive nature, easy repeatability, and possibility to be performed even in patients with severe airway obstruction. It is considered as an indicator of T2 inflammation and, by the same token, a useful predictor for inhaled steroid response. It is difficult to determine the utility of nitric oxide (NO) for initial asthma diagnosis. In such a heterogenous disease, a single parameter would probably not be enough to provide a complete picture. There is also an important variability among authors concerning FeNO cutoff values and the percentage of sensibility and specificity for diagnosis. Its high specificity indicates a potential role to “rule in” asthma; however, its lower sensibility could suggest a lower capacity to “rule out” this pathology. For this reason, if a diagnosis of asthma is being considered, FeNO should be considered along with other tests. FeNO has also shown its utility to detect response to steroids, adherence to treatment, and risk of exacerbation. Even though there is not enough quality of evidence to establish overall conclusions, FeNO could be an alternative procedure to diagnose or exclude asthma and also a predictive tool in asthma treated with corticosteroids. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9403133/ /pubmed/36032508 http://dx.doi.org/10.3389/falgy.2022.957106 Text en © 2022 Marcos and Cisneros Serrano. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Allergy
Marcos, María Celeste
Cisneros Serrano, Carolina
What is the added value of FeNO as T2 biomarker?
title What is the added value of FeNO as T2 biomarker?
title_full What is the added value of FeNO as T2 biomarker?
title_fullStr What is the added value of FeNO as T2 biomarker?
title_full_unstemmed What is the added value of FeNO as T2 biomarker?
title_short What is the added value of FeNO as T2 biomarker?
title_sort what is the added value of feno as t2 biomarker?
topic Allergy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403133/
https://www.ncbi.nlm.nih.gov/pubmed/36032508
http://dx.doi.org/10.3389/falgy.2022.957106
work_keys_str_mv AT marcosmariaceleste whatistheaddedvalueoffenoast2biomarker
AT cisnerosserranocarolina whatistheaddedvalueoffenoast2biomarker